pipeline

ABL Bio is the first biotech company in Korea with a bispecific antibody platform that is undergoing clinical trial.

  • ABL001
    Dual VEGF/DLL4 Inhibition
    Overcomes VEGF Therapy
    Resistance
    ABL001 is a bispecific antibody drug targeting VEGF and DLL4 with more potent anti-angiogenic efficacy.
  • IMMUNO-ONCOLOGY
    Bispecific antibody to address current limitations of PD-(L)1 checkpoint inhibitors
    Minimize systemic toxicity known to 4-1BB based immunotherapeutic, increase reponse rate and overcome resistance observed with PD-(L)1 therapy
  • ADC
    ADC showing a better
    therapeutic index
    Developing ADC with a better in vivo pharmacokinetic parameters for drug candidate to cure rare blood cancers.
  • ABL301
    A bispecific antibody targeting aggregated alpha-synuclein
    with BBB (blood brain barrier)
    penetrating activity
    Developing ABL301 bispecific antibody for the treatment of Parkinson’s disease, a representative neurodegenerative disease.

MORE

Notice & News

Latest News on ABL Bio

News

ABL Bio, Announces BCMAx4-1BB Bispecific...

2019-12-10

- Celgene’s BCMAxCD3 Clinical Trial Data Attracts Attention from American Society of Hemat...

View more

News

ABL Bio Announces Strategic Partnership ...

2018-07-26

- Joint Development of Three Bispecific Antibodies… Acquired Global License outside China ...

View more

News

ABL Bio Adopts Novel Bispecific Antibody...

2018-02-25

- US$220.5 million License-in Agreement on WuXiBody TM Bispecific Antibody Platform and Two ...

View more

MORE

INVESTOR RELATIONS

Information on ABL Bio's IR

career

ABL Bio History

ABL Bio

2019

  • 01

    No. 1 Biotech in Korea

  • 02

    Became the leader among biotech firms in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases using bispecific antibody.

2018

  • 06

    Series C Funding (paid-in capital of 70 billion KRW, June)

  • 07

    Multiple contracts on bispecific antibody program and technology transfer

  • 12

    IPO on KOSDAQ, Dec. 19, 2018 (90 billion KRW of public offering)

MORE